Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment

An Information and Communication Technology-based Centralized Clinical Trial to Determine the Efficacy and Safety of Insulin Dose Adjustment Education Based on a Smartphone Personal Health Record Application

Sponsors

Lead Sponsor: Samsung Medical Center

Collaborator: Ministry of Trade, Industry & Energy, Republic of Korea
Korea Evaluation Institute of Industrial Technology
Daegu Metropolitan City, Korea
ICT Clinical Trial Coordination Center

Source Samsung Medical Center
Brief Summary

This is a 24-week, open-label, randomized, multi-center trial conducted in three tertiary hospitals. There are three follow-up measures; at baseline, post-intervention at Week 12, and Week 24. Subjects are diagnosed as type 1 DM, type 2 DM, and/or post-transplant DM, and initiate or currently use insulin therapy. After the given education on insulin dose titration and prevention for hypoglycemia and 1 week of run-in period, subjects are randomized in a 1:1 ratio to either the ICT-based intervention group or the conventional intervention group. Subjects in conventional intervention group will save and send their health information to the server via the PHR app, whereas those in ICT-based intervention group have additional algorithm-based feedback messages. The health information includes levels of blood glucose, insulin dose, details on hypoglycemia, food diary, and number of steps. The primary outcome will be the proportion of patients who reach an optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits. This study is based upon work supported by the Ministry of Trade, Industry & Energy (MOTIE, Korea) under Industrial Technology Innovation Program (No. 10059066, 'Establishment of ICT Clinical Trial System and Foundation for Industrialization.")

Detailed Description

This is a 24-week, open, randomized, multi-center ICT-based clinical trial conducted in three different hospitals including Samsung Medical Center, Kangbuk Samsung Hospital, and Samsung Changwon Hospital. There are three follow-up measures; at baseline, post-intervention at Week 12, and Week 24. Subjects diagnosed as T1DM, T2DM, and/or post-transplant DM who initiate or currently use insulin therapy will be given education on insulin injection, dose adjustment, and prevention for hypoglycemia and provided at-home measurement device at Visit 1 for screening. Subjects will receive instructions to check daily glucose levels by home glucose meter, to record insulin regimen and dose, the hypoglycemia diary if blood glucose <70 mg/dL or a hypoglycemic event occurs in the apps, and to synchronize data for automatically transferring to system. Subjects who synchronized their information more than once during 1 week of run-in period will be selected into clinical trial and randomly assigned to either ICT-based intervention group or conventional intervention group at a ratio of 1:1. After the randomization, at Week 1, diabetes educators provide telephone counselling for re-instructing insulin dose adjustment and for re-confirming their use of at-home measurement device and PHR apps at Visit 2 (televisit). Subjects in ICT-based intervention group will have algorithm-based feedback messages when their glucose levels are out of ranges, in addition to recording, saving and sending their data to the server via the PHR app, and those in conventional intervention group will only record, save and send their data to the server via the PHR app. Investigators examine the saved health information such as levels of blood glucose, insulin dose, details on hypoglycemia recorded in hypoglycemia diary, food diary, and number of steps transferred through PHR apps. At each clinical visit, anthropometric parameters, current medication use including types of insulin, insulin dose, and other glucose-lowering agents, vital signs, body composition, and questionnaire for satisfaction investigation are examined face-to-face, and blood tests are performed. The unscheduled visit to clinic could be applied if a subject has one or more severe hypoglycemia (requiring other help for recovery) during the study period, or hypoglycemia (<70 mg/dL) twice or more times per week, or fasting blood glucose >200 mg/dL three or more times in the morning, and wants to see a doctor during Week 1-12. The unscheduled visit to clinic is also allowed to the subjects who have difficulty in insulin dose adjustment despite of two or more unscheduled tele-visit. However, even if this criterion does not apply, patients who initiate insulin or change their regimen (eg, from basal insulin once daily to premixed insulin or multiple dose insulin injections) will be allowed to have additional planned doctor visits prior to Visit 3, which is not included in the unscheduled visit, but will be evaluated as scheduled additional visit. The primary outcome will be the proportion of patients who reach an optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits.

Overall Status Completed
Start Date 2017-09-26
Completion Date 2018-12-30
Primary Completion Date 2018-09-30
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
the proportion of patients who reach his/her optimal insulin dose within 12 weeks of enrolling in the study without severe hypoglycemia or unscheduled clinic visits. Week 12
Secondary Outcome
Measure Time Frame
the proportion of patients who reach HbA1c <7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 24 Week 24
the proportion of patients who reach HbA1c <7% without severe hypoglycemia (unrecoverable hypoglycemia without the help of others) at Week 12 Week 12
mean fasting blood glucose values for three consecutive days prior to Week 12 and Week 24 Week 12 and 24
levels of HbA1c at Week 12 and Week 24 Week 12 and Week 24
lipid profile at Week 12 and Week 24 Week 12 and 24
the proportion of patients having hypoglycemia (total, asymptomatic, daytime, nighttime, severe hypoglycemia, and coma/convulsions) at Week 12 and Week 24 Week 12 and Week 24
the number of steps during Week 1-12 and Week 13-24 Week 12 and Week 24
recorded exchange unit by food group Week 12 and 24
daily insulin dose Week 12 and Week 24
blood pressure Week 12 and Week 24
body weight Week 12 and Week 24
lean body mass Week 12 and 24
fat mass Week 12 and 24
Satisfaction evaluation by questionnaire for ICT-based centralized clinical trial monitoring Week 12 and 24
Satisfaction evaluation by DTSQ Week 12 and 24
the number of telephone counselling by diabetes educators Week 12 and 24
the number of self-monitoring blood glucose measurements Week 12 and 24
Enrollment 112
Condition
Intervention

Intervention Type: Device

Intervention Name: Algorithm-based feedback messages

Description: ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention

Arm Group Label: ICT-based intervention

Intervention Type: Device

Intervention Name: Personal Health Record

Description: Subjects will save and send their health information to the server via the personal health record app

Eligibility

Criteria:

Inclusion Criteria 1. age between 18-69 years 2. diagnosis of T1DM, T2DM, and/or post-transplant DM (Post-transplant DM includes both diagnosed T1DM or T2DM before organ transplantation and first diagnosed DM after organ transplantation) 3. initiation or current use of insulin therapy including once-daily basal insulin (including basal insulin only or basal insulin plus rapid-acting insulin), premixed insulin, or NPH) 4. most recent hemoglobin A1c (HbA1c) ≥7.0% based on the National Glycohemoglobin Standardization Program (NGSP) at least 3 months prior to participation (recent HbA1c values measured <3 months prior to screening are permitted.) 5. available to use smartphone and wireless internet 6. Voluntarily write consent to participate in the trial Exclusion criteria 1. on insulin pump 2. history of alcohol or drug abuse 1 year prior to participation 3. history of psychological disorder (e.g., schizophrenia, depression, or bipolar disorder) 4. history of severe visual or hearing impairment 5. pregnant 6. any condition, in the investigator's opinion, not suitable for enrollment eligibility.

Gender:

All

Minimum Age:

18 Years

Maximum Age:

69 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Sang-Man Jin, MD PhD Study Chair Samsung Medical Center
Location
Facility: Samsung Medical Center
Location Countries

Korea, Republic of

Verification Date

2019-04-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Samsung Medical Center

Investigator Full Name: Sang-Man Jin

Investigator Title: Assistant professor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: ICT-based intervention

Type: Active Comparator

Description: Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention

Label: Conventional intervention group

Type: Placebo Comparator

Description: Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app

Acronym ICT
Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Intervention Model Description: randomized in a 1:1 ratio to either the information and communication technology(ICT)-based intervention group or the conventional intervention group

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News